MorphoSys AG logo

MOR - MorphoSys AG Share Price

€108.3 -3.4  -3.0%

Last Trade - 14/08/20

Large Cap
Market Cap £3.30bn
Enterprise Value £2.57bn
Revenue £265.1m
Position in Universe 199th / 1031
Unlock MOR Revenue
Relative Strength (%)
1m +0.93%
Volume Change (%)
10d / 3m
Price vs... (%)
52w High -23.7%
50d MA
200d MA
Growth & Value
12m Forecast Rolling Industry Market
Valuation (ttm) Industry Market
Margin of Safety
Qualifying GuruScreens
Financial Summary
Year End 31st Dec 2014 2015 2016 2017 2018 2019 2020E 2021E CAGR / Avg
64.0 106.2 49.7 66.8 76.4 71.8 312.5 254.8 +2.3%
Balance Sheet
FINANCIAL BRIEF: : For the six months ended 30 June 2020, MorphoSys AG revenues increased from EUR48.2M to EUR269.7M. Net income totaled EUR179.8M vs. loss of EUR28.5M. Revenues reflect Partnered Discovery segment increase from EUR33.7M to EUR245.4M, Proprietary Development segment increase of 67% to EUR24.2M, USA and Canada segment increase from EUR13.6M to EUR266M. Net Income reflects Other Income increase from EUR320K to EUR10.3M (income).
Health Trend(F-Score)
0 1 2 3 4 5 6 7 8 9
Bankruptcy Score(Z-Score)
Earnings Manipulation Risk(M-Score)
Other Ratios
Recent History
Latest interim period vs. prior period Industry Market
3yr Compound Annual Growth Rate Industry Market
Graphical History


MOR Revenue Unlock MOR Revenue

Net Income

MOR Net Income Unlock MOR Revenue

Normalised EPS

MOR Normalised EPS Unlock MOR Revenue

PE Ratio Range

MOR PE Ratio Range Unlock MOR Revenue

Dividend Yield Range

MOR Dividend Yield Range Unlock MOR Revenue
Analyst Forecasts
Price Target:
( below Price)
31st Dec 2020
31st Dec 2021
Est. Long Term Growth Rate: Net Profit
Net Profit
Consensus Estimate
1m Change
3m Change
Analyst Consensus
Strong Sell Sell Hold Buy Strong Buy
EPS 2019 /  2020
MOR EPS Forecasts Unlock MOR Revenue
Profile Summary

MorphoSys AG develops and commercializes antibodies for therapeutic applications. The Company develops drugs using its own research and development, as well as in cooperation with pharmaceutical and biotechnology partners. The Company's operating segments include Proprietary Development and Partnered Discovery. In the Proprietary Development segment, it develops therapeutic antibodies and peptides in the area of inflammatory disease and oncology. In the Partnered Discovery segment, the Company applies technologies for the research, development and optimization of therapeutic antibodies as drug candidates. The Company develops new treatments for patients suffering from serious diseases. Its technologies include HuCAL, which is a collection fully human antibodies and a system for their optimization; Ylanthia, which is an antibody library in Fab format, and Slonomics, an automated technology for gene synthesis and modification for the generation of gene libraries in a controlled process.

Last Annual December 31st, 2019
Last Interim June 30th, 2020
Public Since March 9, 1999
No. of Shareholders: n/a
No. of Employees: 572
Sector Healthcare
Industry Biotechnology & Medical Research
Index Xetra Prime All Share ,
Exchange XETRA
Shares in Issue 32,717,638
Free Float (0.0%)
Eligible for
MOR Share Price Performance
Share Price
Bid - Ask
Low - High
Day's Change
Avg Volume
Open - Close
Range (12m)
Latest News for MOR
Upcoming Events for MOR
Wednesday 11th November, 2020
Q3 2020 MorphoSys AG Earnings Release
Thursday 12th November, 2020
Q3 2020 MorphoSys AG Earnings Call
Saturday 5th December, 2020
MorphoSys AG ASH Annual Meeting & Exposition
Frequently Asked Questions for MorphoSys AG
What is the MorphoSys AG share price?

As of 14/08/20, shares in MorphoSys AG are trading at €108.3, giving the company a market capitalisation of £3.30bn. This share price information is delayed by 15 minutes.

How has the MorphoSys AG share price performed this year?

Shares in MorphoSys AG are currently trading at €108.3 and the price has moved by 3.96% over the past 365 days. In terms of relative price strength - which takes into account the overall market trend - the MorphoSys AG price has moved by 3.49% over the past year.

What are the analyst and broker recommendations for MorphoSys AG?

Of the analysts with advisory recommendations for MorphoSys AG, there are there are currently 6 "buy" , 4 "hold" and 0 "sell" recommendations. The overall consensus recommendation for MorphoSys AG is Buy. You can view the full broker recommendation list by unlocking its StockReport.

When will MorphoSys AG next release its financial results?

MorphoSys AG is scheduled to issue upcoming financial results on the following dates:

Interim results are scheduled for: 2021-06-30
What is the MorphoSys AG dividend yield?

MorphoSys AG does not currently pay a dividend.

Does MorphoSys AG pay a dividend?

MorphoSys AG does not currently pay a dividend.

When does MorphoSys AG next pay dividends?

MorphoSys AG does not currently pay a dividend.

How do I buy MorphoSys AG shares?

To buy shares in MorphoSys AG you'll need a share-dealing account with an online or offline stock broker. Once you have opened your account and transferred funds into it, you'll be able to search and select shares to buy and sell. You can use Stockopedia’s share research software to help you find the the kinds of shares that suit your investment strategy and objectives.

What is the market cap of MorphoSys AG?

Shares in MorphoSys AG are currently trading at €108.3, giving the company a market capitalisation of £3.30bn.

Where are MorphoSys AG shares listed? Where are MorphoSys AG shares listed?

Here are the trading details for MorphoSys AG:

Country of listing: Germany
Exchange: GER
Ticker Symbol: MOR
What kind of share is MorphoSys AG?

Based on an overall assessment of its quality, value and momentum, MorphoSys AG is currently classified as a High Flyer. The classification is based on a composite score that examines a wide range of fundamental and technical measures. Stock are classified on the the following spectrum: Super Stocks, High Flyers, Contrarians, Turnarounds, Neutral, Value Traps, Momentum Traps, Falling Stars, and Sucker Stocks. For more information, learn about our StockRank Styles.

Is there a MorphoSys AG share price forecast 2020?

Shares in MorphoSys AG are currently priced at €108.3. At that level they are trading at 16.38% discount to the analyst consensus target price of 0.00.

Analysts covering MorphoSys AG currently have a consensus Earnings Per Share (EPS) forecast of 0.599 for the next financial year.

How can I tell whether the MorphoSys AG share price will go up?

An important predictor of whether a stock price will go up is its track record of momentum. Price trends tend to persist, so it's worth looking at them when it comes to a share like MorphoSys AG. Over the past six months, the relative strength of its shares against the market has been 13.93%. At the current price of €108.3, shares in MorphoSys AG are trading at 2.53% against their 200 day moving average. You can read more about the power of momentum in assessing share price movements on Stockopedia.

What is the MorphoSys AG PE Ratio?

The MorphoSys AG PE ratio based on its reported earnings over the past 12 months is 34.92. The shares are currently trading at €108.3.

The PE ratio (or price-to-earnings ratio) is the one of the most popular valuation measures used by stock market investors. It is calculated by dividing a company's price per share by its earnings per share.

The PE ratio can be seen as being expressed in years, in the sense that it shows the number of years of earnings which would be required to pay back the purchase price, ignoring inflation. So in general terms, the higher the PE, the more expensive the stock is.

Who are the key directors of MorphoSys AG?

MorphoSys AG's management team is headed by:

Simon Moroney - CEO
Jens Holstein - CFO
Marc Cluzel - CSU
Wendy Johnson - IND
Frank Morich - VSU
Malte Peters - MGB
Markus Enzelberger - CSO
George Golumbeski - SUB
Michael Brosnan - SUB
Krisja Vermeylen - SUB
Jennifer Herron - EVP
Sarah Fakih - VPR
David Trexler - CEX
Jean-Paul Kress - CEO
Sharon Curran - IND
Roland Wandeler - MGB
Who are the major shareholders of MorphoSys AG?

Here are the top five shareholders of MorphoSys AG based on the size of their shareholding:

Baillie Gifford & Co. Investment Advisor
Percentage owned: 6.23% (2.05m shares)
BlackRock Investment Management (UK) Ltd. Investment Advisor/Hedge Fund
Percentage owned: 5.51% (1.81m shares)
Invesco Advisers, Inc. Investment Advisor
Percentage owned: 4.99% (1.64m shares)
T. Rowe Price International (UK) Ltd. Investment Advisor/Hedge Fund
Percentage owned: 3.14% (1.03m shares)
Norges Bank Investment Management (NBIM) Sovereign Wealth Fund
Percentage owned: 2.94% (967k shares)
Similar to MOR
© Stockopedia 2020, Refinitiv, Share Data Services.
This site cannot substitute for professional investment advice or independent factual verification. To use it, you must accept our Terms of Use, Privacy and Disclaimer policies.